Pollens - grasses, redtop agrostis alba - Biologic Drug Details

Summary for pollens - grasses, redtop agrostis alba

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, redtop agrostis alba

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Non-Standardized Pollen Allergenic Extract Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, redtop agrostis alba Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, redtop agrostis alba Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, redtop agrostis alba Derived from Patent Text Search

No patents found based on company disclosures

Pollens - grasses, redtop agrostis alba Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biologic Drugs: Grass Pollen Allergies, Including Redtop (Agrostis alba)

Introduction to Grass Pollen Allergy Drugs

Grass pollen allergies are a common issue affecting millions worldwide, leading to symptoms such as sneezing, itching, and watery eyes. The market for grass pollen allergy drugs, including those targeting Redtop (Agrostis alba), is experiencing significant growth driven by several key factors.

Market Growth and CAGR

The global grass pollen allergy drug market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 7.1% from 2024 to 2031. This growth is fueled by increasing awareness about allergies, advancements in healthcare technologies, and the rising demand for personalized medicine[1].

Key Market Trends

Personalized Medicine

Advancements in technology have enabled more personalized treatment options based on individual patient factors such as genetics and allergy severity. This trend is expected to drive innovation and patient satisfaction in the market[1].

Biologic Therapies

The development of biologic drugs offers new, targeted options for managing grass pollen allergies with potentially fewer side effects than traditional medications. Biologics are becoming increasingly popular due to their efficacy and safety profiles[1].

Market Consolidation

Mergers and acquisitions in the pharmaceutical industry are leading to increased competition and innovation in the grass pollen allergy drug market. This consolidation can result in more robust research and development efforts, benefiting patients and the market as a whole[1].

Product Types and Market Segmentation

The grass pollen allergy drug market is segmented into various product types, including:

BM-32 and Pollinex Quattro Grass

These are two commonly used types of grass pollen allergy drugs. Pollinex Quattro Grass is particularly dominant due to its effectiveness in desensitizing the immune system to allergens[1].

Other Treatments

Other treatments include immunotherapy, antihistamines, and corticosteroids. Standardized allergenic extracts, such as those from Redtop (Agrostis alba), are used for diagnosis and treatment through hyposensitization therapy[2].

Geographic Market Analysis

The market for grass pollen allergy drugs is global, with significant growth observed in various regions:

North America and Europe

These regions are expected to remain lucrative due to high awareness about allergies and the availability of advanced treatment options. North America, in particular, is driven by FDA approvals of novel medications for pollen allergy treatment[4].

Middle East & Africa

Countries such as Turkey, Saudi Arabia, and the UAE are experiencing growth driven by increasing incidence of allergies and growing awareness about preventive healthcare[1].

Key Players and Competitive Landscape

Several key players are driving the market forward through innovation and strategic partnerships:

ALK-Abello A/S, Allergy Therapeutics Plc, Biomay AG

These companies, along with others like Circassia Pharmaceuticals Plc, HAL Allergy BV, and Roxall Medizin GmbH, are focusing on expanding their product portfolios, developing new therapies, and investing in research and development to cater to the rising demand for grass pollen allergy drugs[1].

Innovative Growth Drivers

Novel Drug Formulations

The development of novel drug formulations with improved efficacy and safety profiles is a significant growth driver. These formulations often incorporate advanced technologies such as personalized medicine and precision dosing[1].

Strategic Partnerships and Collaborations

Collaborations between pharmaceutical companies and research institutions are expected to drive innovation and accelerate the entry of new products into the market. These partnerships can lead to more effective and targeted treatments[1].

Deployment Strategies

Online Pharmacies and Telemedicine

Expanding market access through online pharmacies and telemedicine services can enhance the reach and accessibility of grass pollen allergy drugs. This is particularly beneficial in regions with limited healthcare infrastructure[1].

Digital Platforms for Marketing and Patient Education

Leveraging digital platforms for targeted marketing and patient education can increase awareness and adherence to treatment plans. A patient-centric approach, including personalized treatment plans and patient support programs, can further enhance patient satisfaction and market growth[1].

Financial Trajectory

The financial trajectory of the grass pollen allergy drug market is promising, with significant revenue growth anticipated:

Market Size and Forecast

The market is expected to grow annually by 7.1% from 2024 to 2031, driven by the factors mentioned above. This growth will be reflected in increased revenues for pharmaceutical companies involved in this sector[1].

Revenue Streams

Revenue will come from various sources, including the sale of biologic drugs, immunotherapy treatments, and other allergy medications. The market's financial health will also be influenced by research and development investments, strategic partnerships, and market expansion strategies[1].

Redtop (Agrostis alba) Specifics

Allergen Information

Redtop (Agrostis alba) is a common allergenic grass found in most US states except Hawaii, Florida, North Carolina, and South Dakota. It is often used for erosion control and in pastures due to its quick germination and rhizomatous perennial nature[5].

Treatment Options

Standardized allergenic extracts from Redtop are used in hyposensitization therapy to treat patients with a history of allergy to this specific grass pollen. These extracts are carefully standardized to ensure consistent potency and safety[2].

Key Takeaways

• The global grass pollen allergy drug market is growing at a CAGR of 7.1% from 2024 to 2031.
• Personalized medicine, biologic therapies, and market consolidation are key trends driving this growth.
• The market is segmented into various product types, including BM-32, Pollinex Quattro Grass, and other treatments like immunotherapy and antihistamines.
• Key players are investing heavily in research and development to cater to the rising demand.
• Innovative growth drivers include novel drug formulations, strategic partnerships, and the use of digital platforms.
• The financial trajectory is promising, with significant revenue growth anticipated.

FAQs

What is the expected CAGR for the grass pollen allergy drug market from 2024 to 2031?

The grass pollen allergy drug market is anticipated to grow annually by 7.1% from 2024 to 2031[1].

What are the key trends driving the growth of the grass pollen allergy drug market?

Key trends include personalized medicine, biologic therapies, and market consolidation[1].

Which regions are expected to be most lucrative for the grass pollen allergy drug market?

North America and Europe are expected to remain lucrative due to high awareness about allergies and the availability of advanced treatment options[1][4].

What role do standardized allergenic extracts play in treating grass pollen allergies?

Standardized allergenic extracts, such as those from Redtop (Agrostis alba), are used for diagnosis and treatment through hyposensitization therapy[2].

How are pharmaceutical companies expanding their market reach for grass pollen allergy drugs?

Companies are expanding market access through online pharmacies, telemedicine services, and leveraging digital platforms for targeted marketing and patient education[1].

What is the significance of Redtop (Agrostis alba) in the context of grass pollen allergies?

Redtop is a common allergenic grass used in standardized allergenic extracts for hyposensitization therapy, and it is widely distributed across the US except for a few states[5].

Sources

1. Global Grass Pollen Allergy Drug Market Trends - HackMD
2. PRODUCT MONOGRAPH - ALK - ALK-Abelló
3. Integrated Invasive Plant Management for the Medford District - BLM
4. Global Ragweed Pollen Allergy Treatment Market - Business Wire
5. Redtop: Allergen Information & Map - Stallergenes Greer